معرفی
Celine Meinguet is a medicinal chemist and cancer researcher at the Department of Pharmacy, Faculty of Science, University of Namur. She completed her Doctor of Sciences in 2015 with a thesis focused on harmine derivatives as anticancer agents, working under the supervision of Professor Jean Wouters. Her research career spans over a decade with significant contributions to medicinal chemistry and cancer pharmacology.
Meinguet's educational background includes a Master in Chemistry completed in 2011 with her thesis "Etude structurale et enzymatique de l'indoléamine 2,3-dioxygénase" (Structural and enzymatic study of indoleamine 2,3-dioxygenase), also supervised by Jean Wouters. Her academic journey reflects a strong focus on biochemical and pharmaceutical sciences with applications in cancer research.
Her primary research interests center on the development of harmine-derived compounds as anticancer agents, particularly beta-carboline structures that target protein synthesis in cancer cells. She has also made significant contributions to the study of indoleamine 2,3-dioxygenase inhibitors and contact pathway inhibitors for thrombosis prevention. The research fingerprint shows strong emphasis on synthesis (100%), inhibition (72%), and harmine-related cancer research (66%), reflecting her expertise in medicinal chemistry approaches to cancer therapeutics.
Analysis of her publication record reveals a concentration of impactful work in 2017, with multiple publications on harmine-derived beta-carbolines and their anti-cancer mechanisms. Her research demonstrates a consistent focus on translating chemical synthesis into biological activity, with particular attention to molecular targeting in cancer cells.
Her scientific recognition includes:
- best oral communication award (June 5, 2013)
Meinguet has been actively involved in numerous research projects, including as Principal Investigator on "Synthèse, caractérisation physico-chimique, évaluations biologique et pharmaceutique de dérivés de l'harmine en tant qu'anticancéreux" (2010-2015). She has participated extensively in academic conferences and workshops between 2011-2014, including serving on the organizing committee for the Doctoral School on Structure and Function of Biological Macromolecules.
Her laboratory work focuses on the synthesis and characterization of novel anticancer compounds, with particular expertise in crystallographic analysis of drug candidates. The research team she has collaborated with includes prominent researchers in medicinal chemistry and pharmacology at the University of Namur.
